Cited 7 times in
Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 이혜원 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2018-08-28T16:50:38Z | - |
dc.date.available | 2018-08-28T16:50:38Z | - |
dc.date.issued | 2018 | - |
dc.identifier.issn | 0146-6615 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/161998 | - |
dc.description.abstract | It is unclear whether chronic hepatitis B (CHB) patients with antiviral resistance, who achieve a complete virologic response (CVR) with tenofovir disoproxil fumarate (TDF) and nucleoside analogue (NUC) combination therapy, maintain CVR if switched to TDF monotherapy. We investigated the persistence of CVR after cessation of NUC in virologically suppressed antiviral resistant CHB patients using TDF+NUC combination therapy. This study recruited 76 antiviral-resistant CHB patients showing CVR on TDF+entecavir (ETV) (n = 52), TDF+lamivudine (LAM; n = 14), and TDF+telbivudine (LdT; n = 10) combination therapy, who were switched to TDF monotherapy as step-down therapy. At baseline, 47 patients were male and the median age was 53.0 years (range: 30-78 years); 72.3% cases were hepatitis B e antigen-positive (HBeAg+) and 23.7% were of liver cirrhosis. The median duration of TDF+NUC combination therapy was 20.8 months (range: 3-46 months). At a median follow-up of 24.7 months (range: 12-48 months) after switching to TDF monotherapy, all 76 patients maintained CVR, regardless of the duration of combination therapy and the type of prior NUC and antiviral resistance. Renal dysfunction was not observed during the treatment period. The step-down strategy of switching from TDF+NUC combination therapy to TDF monotherapy in virologically suppressed CHB patients with antiviral resistance should be considered. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Wiley-Liss | - |
dc.relation.isPartOf | JOURNAL OF MEDICAL VIROLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | Switching from tenofovir and nucleoside analogue therapy to tenofovir monotherapy in virologically suppressed chronic hepatitis B patients with antiviral resistance | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Dong Yun Kim | - |
dc.contributor.googleauthor | Hye Won Lee | - |
dc.contributor.googleauthor | Jeong Eun Song | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.identifier.doi | 10.1002/jmv.24986 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A03318 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J01587 | - |
dc.identifier.eissn | 1096-9071 | - |
dc.identifier.pmid | 29077211 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.24986 | - |
dc.subject.keyword | chronic hepatitis B | - |
dc.subject.keyword | drug resistance | - |
dc.subject.keyword | hepatitis B virus | - |
dc.subject.keyword | step-down therapy | - |
dc.subject.keyword | tenofovir | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Lee, Hye Won | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Lee, Hye Won | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.citation.volume | 90 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 497 | - |
dc.citation.endPage | 502 | - |
dc.identifier.bibliographicCitation | JOURNAL OF MEDICAL VIROLOGY, Vol.90(3) : 497-502, 2018 | - |
dc.identifier.rimsid | 59589 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.